Redcare Pharmacy's Prescription for a Turnaround

Redcare Pharmacy's Q1 2026 revenue beats forecasts with a 35% surge in prescription sales. New CFO appointed as company defends its dominant Rx market share against new competitors.

A surprise surge in prescription sales has given Redcare Pharmacy a much-needed boost, sending its shares soaring by over 14% in a single session. The online pharmacy’s preliminary first-quarter figures for 2026 handily beat market expectations, driven by a powerful performance in its core German market.

Group revenue climbed 18.3% to €848 million, surpassing the analyst consensus of €837 million. The real story, however, was the Rx segment. Revenue from prescription medications jumped 35% to €315 million across the company. In Germany, this business exploded by 55% to €168 million, significantly outpacing forecasts of €162 million. Even the previously sluggish over-the-counter (OTC) segment showed signs of life, with growth accelerating to 9.7% from 5.4% in the prior quarter.

This operational momentum arrives at a pivotal moment for the company’s leadership. At the Annual General Meeting on April 15, Hendrik Krampe will be officially confirmed as the new Chief Financial Officer. Krampe, who previously led Amazon’s European marketplace business for eight years, is seen as a key asset for scaling Redcare’s digital platform.

Despite the day’s sharp gain, the stock’s broader performance remains a concern. Trading at €39.44, the share price is still down more than 41% since the start of the year, ranking it among the weakest performers in Germany’s MDAX index. The company’s full quarterly report, due on May 6, will be the first major test for the new management team to provide detailed evidence supporting its full-year outlook.

The competitive landscape is intensifying. The entry of drugstore chain dm into the online pharmacy market in late 2025 and similar considerations from rival Rossmann have unsettled investors. Rossmann has confirmed it will not offer prescription drugs, a decision that preserves Redcare’s critical "moat" in the lucrative Rx sector, where it holds a commanding 67% market share in Germany.

Beyond competition, a potential policy shift could provide a tailwind. A finance commission has proposed increasing patient co-payments for prescription drugs by 50%. Higher out-of-pocket costs are expected to drive more price-sensitive consumers from local pharmacies to cheaper online alternatives like Redcare.

Management has reaffirmed its 2026 targets, which include total revenue growth of 13% to 15%, German Rx revenue exceeding €670 million, and an adjusted EBITDA margin of at least 2.5%. The company’s customer base expanded to 14.2 million active users, up from 13.1 million a year earlier. User satisfaction with its digital prescription service also improved, as measured by a Net Promoter Score increase from 73 to 76.

Analyst firm Jefferies maintained its "Buy" rating on the stock with a price target of €150 following the results. The coming months will reveal whether this prescription-driven surge is a one-off remedy or the beginning of a sustained recovery for the online pharmacy giant.